Editor's Corner: Fierce Biotech's top 10 most read stories in 2021 BioNTech CEO applies COVID-19 vaccine's mRNA tech to multiple sclerosis Novavax targets May approval for COVID-19 vaccine in the U.S. Sabatini, biotech founder and mTOR pioneer, ousted after sexual harassment investigation Merck has better luck with 2nd COVID-19 drug attempt as it sees a positive in early molnupiravir data He authorized Moderna's vaccine 6 months ago. Now, ex-FDA chief Hahn joins biotech's backer AHA: AstraZeneca, Moderna shine early light on mRNA potential in heart failure Novavax COVID-19 vaccine 90% efficacious in phase 3, but protection plummets against one variant Johnson & Johnson's closely watched single-shot COVID-19 vaccine readout 'next week' as CFO sees 'robust data' Eli Lilly's Alzheimer's moment has arrived after Biogen plows through the FDA gates Moderna's RSV vaccine catches the fast track on heels of Pfizer's leapfrog into the queue Featured Story | By Annalee Armstrong You may sense a theme in our top 10 most read stories this year, and it’s not a surprise. Six out of 10 stories had something to do with COVID-19. read more |
| |
|---|
|
|
| Webinar: Improving the discovery of novel drugs with artificial intelligence Thursday, February 3, 2022 | 2pm ET / 11am PT This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now. |
Top Stories By Angus Liu The new vaccine technology mRNA is making waves these days as COVID-19 shots based on it deliver efficacy that’s unrivaled by other platforms. BioNTech's Pfizer-partnered vaccine Comirnaty is one of those vaccines. Now, the German biotech’s CEO, Ugur Sahin, has led a study showing an mRNA vaccine was effective against multiple sclerosis in mice. read more By Nick Paul Taylor Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The goal suggests the U.S. could join the U.K. on the list of countries to authorize the vaccine in the first half of the year. read more By Nick Paul Taylor David Sabatini, the scientific founder of several biotechs, has been ousted from his lab after a sexual harassment investigation. The high-profile cell signaling and cancer metabolism scientist is “no longer associated” with either the Whitehead Institute or the Howard Hughes Medical Institute. read more By Ben Adams Merck has had a torrid time with COVID-19 vaccines and a major setback with its OncoImmune-partnered pandemic med, but now, finally, it’s seeing some good news on that R&D front. read more By Kyle LaHucik Ex-FDA Commissioner Stephen Hahn, M.D., is joining Moderna incubator Flagship Pioneering six months after granting the company an emergency use authorization for its COVID-19 vaccine. read more By Ben Adams Although AstraZeneca and Moderna are archrivals in the COVID-19 vaccine space, the two have an interesting mRNA pact that has been operating largely under the radar. read more By Nick Paul Taylor Novavax’s COVID-19 vaccine has achieved 89.3% efficacy in a phase 3 clinical trial that enrolled subjects exposed to the B.1.1.7 variant found in the U.K. However, the vaccine performed far worse in a smaller phase 2b that pitted it against another variant first identified in South Africa, intensifying concerns that updated prophylactics will be needed to protect against the evolving virus. read more By Ben Adams While the world struggles with two-shot vaccine production as a handful of pharma companies try to make enough for almost the entire global population, a single-dose option from Johnson & Johnson has become a major hope in the fight against COVID-19. read more By Annalee Armstrong Eli Lilly's neuroscience team has moved quickly since Aduhelm's June approval to get their own therapy, donanemab, to an accelerated approval filing with the FDA by the end of the year. And the Big Pharma is hoping to beat their competitor to the punch with proof their drug actually slows progression of the disease. read more By Annalee Armstrong Moderna has its next act lined up: an mRNA respiratory syncytial virus vaccine, which the FDA has just put on the fast track. The biotech, which made its name in 2020 with its COVID-19 vaccine, has been granted a fast track designation for mRNA-1345, which is under investigation as a single-dose vaccine. read more Resources Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: BBK Worldwide New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce JPM Week 2022 January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA Fierce BD&L Summit March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2022 | Location TBD Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Biotech Virtual Forum October 19, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2022 | Location TBD Fierce European Trial Master File Summit November 2022 | Location TBD | 